IL130065A - Gel preparations for local administration of drugs - Google Patents

Gel preparations for local administration of drugs

Info

Publication number: IL130065A
Authority: IL; Israel
Prior art keywords: formulation; ethanol; ethoxymethyl; amino; percent
Prior art date: 1996-12-03

Application number

IL13006597A

Other languages

English (en)

Hebrew (he)

Other versions

IL130065A0 (en

Original Assignee

Minnesota Mining & Mfg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-03

Filing date

1997-12-01

Publication date

2004-06-20

1997-12-01 Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg

2000-02-29 Publication of IL130065A0 publication Critical patent/IL130065A0/xx

2004-06-20 Publication of IL130065A publication Critical patent/IL130065A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 81
238000009472 formulation Methods 0.000 title claims abstract description 75
230000000699 topical effect Effects 0.000 title description 6
238000012377 drug delivery Methods 0.000 title description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 57
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims abstract description 47
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 28
229940075614 colloidal silicon dioxide Drugs 0.000 claims abstract description 24
235000013773 glyceryl triacetate Nutrition 0.000 claims abstract description 23
239000001087 glyceryl triacetate Substances 0.000 claims abstract description 23
229960002622 triacetin Drugs 0.000 claims abstract description 23
235000013772 propylene glycol Nutrition 0.000 claims abstract description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
238000011200 topical administration Methods 0.000 claims 2
230000003287 optical effect Effects 0.000 abstract 1
239000000499 gel Substances 0.000 description 35
210000004027 cell Anatomy 0.000 description 20
229940079593 drug Drugs 0.000 description 20
239000003814 drug Substances 0.000 description 20
239000012530 fluid Substances 0.000 description 17
102000014150 Interferons Human genes 0.000 description 14
108010050904 Interferons Proteins 0.000 description 14
102000004127 Cytokines Human genes 0.000 description 13
108090000695 Cytokines Proteins 0.000 description 13
229940079322 interferon Drugs 0.000 description 13
108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
238000000034 method Methods 0.000 description 11
238000010998 test method Methods 0.000 description 11
102000003390 tumor necrosis factor Human genes 0.000 description 11
230000006698 induction Effects 0.000 description 10
238000009792 diffusion process Methods 0.000 description 9
210000004379 membrane Anatomy 0.000 description 9
239000012528 membrane Substances 0.000 description 9
150000001875 compounds Chemical class 0.000 description 8
241000699670 Mus sp. Species 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
238000003756 stirring Methods 0.000 description 5
230000001186 cumulative effect Effects 0.000 description 4
239000011521 glass Substances 0.000 description 4
230000035515 penetration Effects 0.000 description 4
238000005070 sampling Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
206010059313 Anogenital warts Diseases 0.000 description 3
208000000907 Condylomata Acuminata Diseases 0.000 description 3
208000009889 Herpes Simplex Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
208000025009 anogenital human papillomavirus infection Diseases 0.000 description 3
201000004201 anogenital venereal wart Diseases 0.000 description 3
238000004166 bioassay Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
241000710188 Encephalomyocarditis virus Species 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
210000005056 cell body Anatomy 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
239000008252 pharmaceutical gel Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000007974 sodium acetate buffer Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000012385 systemic delivery Methods 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
229910002012 Aerosil® Inorganic materials 0.000 description 1
239000004254 Ammonium phosphate Substances 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010008263 Cervical dysplasia Diseases 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
208000009621 actinic keratosis Diseases 0.000 description 1
229910000148 ammonium phosphate Inorganic materials 0.000 description 1
235000019289 ammonium phosphates Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229960004756 ethanol Drugs 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
238000005065 mining Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000009854 mucosal lesion Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002245 particle Substances 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
239000008250 pharmaceutical cream Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
-1 polyethylene Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 1
BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
238000002943 spectrophotometric absorbance Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229940042129 topical gel Drugs 0.000 description 1
229940086542 triethylamine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL13006597A 1996-12-03 1997-12-01 Gel preparations for local administration of drugs IL130065A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/759,992 US5939090A (en)	1996-12-03	1996-12-03	Gel formulations for topical drug delivery
PCT/US1997/021995 WO1998024436A2 (en)	1996-12-03	1997-12-01	Gel formulations for topical drug delivery

Publications (2)

Publication Number	Publication Date
IL130065A0 IL130065A0 (en)	2000-02-29
IL130065A true IL130065A (en)	2004-06-20

Family

ID=25057713

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13006597A IL130065A (en)	1996-12-03	1997-12-01	Gel preparations for local administration of drugs

Country Status (18)

Country	Link
US (2)	US5939090A (de)
EP (1)	EP0942724B1 (de)
JP (1)	JP4615633B2 (de)
KR (1)	KR100503716B1 (de)
AT (1)	ATE245422T1 (de)
AU (1)	AU723897B2 (de)
BR (1)	BR9713677B1 (de)
CA (1)	CA2273094C (de)
CZ (1)	CZ301713B6 (de)
DE (1)	DE69723721T2 (de)
DK (1)	DK0942724T3 (de)
ES (1)	ES2200206T3 (de)
HU (1)	HU229599B1 (de)
IL (1)	IL130065A (de)
NO (1)	NO325684B1 (de)
NZ (1)	NZ335821A (de)
PT (1)	PT942724E (de)
WO (1)	WO1998024436A2 (de)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5741908A (en)	1996-06-21	1998-04-21	Minnesota Mining And Manufacturing Company	Process for reparing imidazoquinolinamines
UA67760C2 (uk)	1997-12-11	2004-07-15	Міннесота Майнінг Енд Мануфакчурінг Компані	Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6518280B2 (en)	1998-12-11	2003-02-11	3M Innovative Properties Company	Imidazonaphthyridines
US6486168B1 (en)	1999-01-08	2002-11-26	3M Innovative Properties Company	Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en)	1999-01-08	2002-05-16	Hedenstrom John C.	Systems and methods for treating a mucosal surface
EP1495758A3 (de) *	1999-01-08	2005-04-13	3M Innovative Properties Company	Zubereitungen, enthaltend Imiquimod oder andere Immunantwort modifizierende Verbindungen, zur Behandlung von mukosalen Erkrankungen
PL349773A1 (en) *	1999-01-08	2002-09-09	3M Innovative Properties Co	Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
US6558951B1 (en) *	1999-02-11	2003-05-06	3M Innovative Properties Company	Maturation of dendritic cells with immune response modifying compounds
US6541485B1 (en)	1999-06-10	2003-04-01	3M Innovative Properties Company	Urea substituted imidazoquinolines
US6573273B1 (en)	1999-06-10	2003-06-03	3M Innovative Properties Company	Urea substituted imidazoquinolines
US6331539B1 (en) *	1999-06-10	2001-12-18	3M Innovative Properties Company	Sulfonamide and sulfamide substituted imidazoquinolines
US6756382B2 (en) *	1999-06-10	2004-06-29	3M Innovative Properties Company	Amide substituted imidazoquinolines
US6916925B1 (en)	1999-11-05	2005-07-12	3M Innovative Properties Co.	Dye labeled imidazoquinoline compounds
US6376669B1 (en)	1999-11-05	2002-04-23	3M Innovative Properties Company	Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) *	1999-12-28	2003-08-11	株式会社デンソー	アクセル装置
US6787342B2 (en) *	2000-02-16	2004-09-07	Merial Limited	Paste formulations
US6894060B2 (en) *	2000-03-30	2005-05-17	3M Innovative Properties Company	Method for the treatment of dermal lesions caused by envenomation
RU2349321C2 (ru) *	2000-06-22	2009-03-20	Такеда Фармасьютикал Компани Лимитед	Системы и способы лечения поверхности слизистых оболочек
CN1273110C (zh) *	2000-06-22	2006-09-06	3M创新有限公司	治疗粘膜面的系统
DE10033853A1 (de) *	2000-07-12	2002-01-31	Hexal Ag	Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US7056533B2 (en)	2000-08-15	2006-06-06	Surmodics, Inc.	Medicament incorporation matrix
US20020055517A1 (en) *	2000-09-15	2002-05-09	3M Innovative Properties Company	Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (ja) *	2000-11-06	2002-05-22	Sumitomo Pharmaceut Co Ltd	アラキドン酸誘発皮膚疾患治療剤
US6545017B1 (en)	2000-12-08	2003-04-08	3M Innovative Properties Company	Urea substituted imidazopyridines
US20060142202A1 (en) *	2000-12-08	2006-06-29	3M Innovative Properties Company	Compositions and methods for targeted delivery of immune response modifiers
US6664264B2 (en) *	2000-12-08	2003-12-16	3M Innovative Properties Company	Thioether substituted imidazoquinolines
US6677347B2 (en) *	2000-12-08	2004-01-13	3M Innovative Properties Company	Sulfonamido ether substituted imidazoquinolines
US6667312B2 (en) *	2000-12-08	2003-12-23	3M Innovative Properties Company	Thioether substituted imidazoquinolines
UA74852C2 (en) *	2000-12-08	2006-02-15	3M Innovative Properties Co	Urea-substituted imidazoquinoline ethers
US6660747B2 (en)	2000-12-08	2003-12-09	3M Innovative Properties Company	Amido ether substituted imidazoquinolines
US6664260B2 (en)	2000-12-08	2003-12-16	3M Innovative Properties Company	Heterocyclic ether substituted imidazoquinolines
US6525064B1 (en)	2000-12-08	2003-02-25	3M Innovative Properties Company	Sulfonamido substituted imidazopyridines
US6664265B2 (en) *	2000-12-08	2003-12-16	3M Innovative Properties Company	Amido ether substituted imidazoquinolines
CA2430206A1 (en) *	2000-12-08	2002-06-13	3M Innovative Properties Company	Screening method for identifying compounds that selectively induce interferon alpha
US6660735B2 (en) *	2000-12-08	2003-12-09	3M Innovative Properties Company	Urea substituted imidazoquinoline ethers
US6677348B2 (en)	2000-12-08	2004-01-13	3M Innovative Properties Company	Aryl ether substituted imidazoquinolines
US6545016B1 (en)	2000-12-08	2003-04-08	3M Innovative Properties Company	Amide substituted imidazopyridines
US7226928B2 (en) *	2001-06-15	2007-06-05	3M Innovative Properties Company	Methods for the treatment of periodontal disease
US20030068375A1 (en)	2001-08-06	2003-04-10	Curtis Wright	Pharmaceutical formulation containing gelling agent
CA2458876A1 (en) *	2001-08-30	2003-03-13	3M Innovative Properties Company	Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
DK1719511T3 (da) *	2001-11-16	2009-04-14	Coley Pharm Group Inc	N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf
IL161786A0 (en) *	2001-11-29	2005-11-20	3M Innovative Properties Co	Pharmaceutical formulations comprising an immune
CA2365732A1 (en) *	2001-12-20	2003-06-20	Ibm Canada Limited-Ibm Canada Limitee	Testing measurements
US6677349B1 (en)	2001-12-21	2004-01-13	3M Innovative Properties Company	Sulfonamide and sulfamide substituted imidazoquinolines
US7030129B2 (en) *	2002-02-22	2006-04-18	3M Innovative Properties Company	Method of reducing and treating UVB-induced immunosuppression
WO2003103584A2 (en)	2002-06-07	2003-12-18	3M Innovative Properties Company	Ether substituted imidazopyridines
DE60317856T2 (de) *	2002-07-08	2008-11-27	Eastman Kodak Co.	Organische ladungstransportpolymere mit Ladungstransportresten und Silangruppen sowie daraus hergestellten Silsesquioxanzusammensetzungen
WO2004032829A2 (en)	2002-08-15	2004-04-22	3M Innovative Properties Company	Immunostimulatory compositions and methods of stimulating an immune response
US6818650B2 (en) *	2002-09-26	2004-11-16	3M Innovative Properties Company	1H-imidazo dimers
AU2003287316A1 (en) *	2002-12-11	2004-06-30	3M Innovative Properties Company	Assays relating to toll-like receptor activity
WO2004053057A2 (en) *	2002-12-11	2004-06-24	3M Innovative Properties Company	Gene expression systems and recombinant cell lines
JP2006513212A (ja)	2002-12-20	2006-04-20	スリーエムイノベイティブプロパティズカンパニー	アリール／ヘタリール置換されたイミダゾキノリン
US7387271B2 (en)	2002-12-30	2008-06-17	3M Innovative Properties Company	Immunostimulatory combinations
JP2006517974A (ja) *	2003-02-13	2006-08-03	スリーエムイノベイティブプロパティズカンパニー	Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
EP1599726A4 (de) *	2003-02-27	2009-07-22	3M Innovative Properties Co	Selektive modulation von tlr-vermittelter biologischer aktivität
WO2004078138A2 (en)	2003-03-04	2004-09-16	3M Innovative Properties Company	Prophylactic treatment of uv-induced epidermal neoplasia
WO2004080398A2 (en) *	2003-03-07	2004-09-23	3M Innovative Properties Company	1-amino 1h-imidazoquinolines
US7163947B2 (en) *	2003-03-07	2007-01-16	3M Innovative Properties Company	1-Amino 1H-imidazoquinolines
KR20050109562A (ko) *	2003-03-13	2005-11-21	쓰리엠 이노베이티브 프로퍼티즈 컴파니	피부의 질을 개선시키는 방법
WO2004080293A2 (en) *	2003-03-13	2004-09-23	3M Innovative Properties Company	Methods for diagnosing skin lesions
AU2004220465A1 (en) *	2003-03-13	2004-09-23	3M Innovative Properties Company	Method of tattoo removal
US20040192585A1 (en)	2003-03-25	2004-09-30	3M Innovative Properties Company	Treatment for basal cell carcinoma
AU2004229478B2 (en) *	2003-04-10	2009-12-24	3M Innovative Properties Company	Delivery of immune response modifier compounds
US20040265351A1 (en) *	2003-04-10	2004-12-30	Miller Richard L.	Methods and compositions for enhancing immune response
WO2004096144A2 (en) *	2003-04-28	2004-11-11	3M Innovative Properties Company	Compositions and methods for induction of opioid receptors
US20050032829A1 (en) *	2003-06-06	2005-02-10	3M Innovative Properties Company	Process for imidazo[4,5-c]pyridin-4-amines
WO2004110991A2 (en) *	2003-06-06	2004-12-23	3M Innovative Properties Company	PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
CA2533128A1 (en) *	2003-07-31	2005-02-10	3M Innovative Properties Company	Bioactive compositions comprising triazines
JP2007501252A (ja) *	2003-08-05	2007-01-25	スリーエムイノベイティブプロパティズカンパニー	免疫応答調整剤を含有する製剤
US8211906B1 (en)	2003-08-05	2012-07-03	Scherrer Lawrence C	Method of inhibiting growth of neoplastic cells and inhibiting infection by administering an immune enhancer drug
WO2005018556A2 (en)	2003-08-12	2005-03-03	3M Innovative Properties Company	Hydroxylamine substituted imidazo-containing compounds
CA2535338C (en) *	2003-08-14	2013-05-28	3M Innovative Properties Company	Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
US20050048072A1 (en) *	2003-08-25	2005-03-03	3M Innovative Properties Company	Immunostimulatory combinations and treatments
CA2536249A1 (en)	2003-08-25	2005-03-10	3M Innovative Properties Company	Delivery of immune response modifier compounds
RU2006105101A (ru)	2003-08-27	2007-10-10	3М Инновейтив Пропертиз Компани (US)	Арилокси и арилалкиленокси замещенные имидазохинолины
AU2004268665A1 (en) *	2003-09-02	2005-03-10	3M Innovative Properties Company	Methods related to the treatment of mucosal associated conditions
WO2005023190A2 (en) *	2003-09-05	2005-03-17	3M Innovative Properties Company	Treatment for cd5+ b cell lymphoma
EP1664342A4 (de) *	2003-09-17	2007-12-26	3M Innovative Properties Co	Selektive modulation der expression des tlr-gens
US7544697B2 (en) *	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
US8871782B2 (en)	2003-10-03	2014-10-28	3M Innovative Properties Company	Alkoxy substituted imidazoquinolines
AR046172A1 (es)	2003-10-03	2005-11-30	3M Innovative Properties Co	Pirazolopiridinas y sus analogos; composiciones farmaceuticas que los contienen y su uso en la inhibicion de la biosintesis de citocinas
US20090075980A1 (en) *	2003-10-03	2009-03-19	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and Analogs Thereof
AU2004285575A1 (en) *	2003-10-31	2005-05-12	3M Innovative Properties Company	Neutrophil activation by immune response modifier compounds
CA2545774A1 (en) *	2003-11-14	2005-06-02	3M Innovative Properties Company	Oxime substituted imidazo ring compounds
US8598192B2 (en)	2003-11-14	2013-12-03	3M Innovative Properties Company	Hydroxylamine substituted imidazoquinolines
CA2547085A1 (en) *	2003-11-25	2005-06-09	3M Innovative Properties Company	Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
AR046781A1 (es)	2003-11-25	2005-12-21	3M Innovative Properties Co	Derivados de imidazoquinolinas. composiciones farmaceuticas.
JP2007513165A (ja) *	2003-12-02	2007-05-24	スリーエムイノベイティブプロパティズカンパニー	Ｉｒｍ化合物を含む併用薬および治療方法
US20050226878A1 (en) *	2003-12-02	2005-10-13	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
US6943470B2 (en) *	2003-12-02	2005-09-13	Siemens Westinghouse Power Corporation	Air gap baffle assembly for gas-cooled turbine generator and method of installing
EP1694674A4 (de) *	2003-12-04	2010-07-07	3M Innovative Properties Co	Sulfonsubstituierte imidazoringether
EP1699792A1 (de) *	2003-12-29	2006-09-13	3M Innovative Properties Company	Piperazin-, [1,4]diazepan-, [1,4]diazocan- und [1,5]diazocan-kondensierte imidazoringverbindungen
WO2005066170A1 (en)	2003-12-29	2005-07-21	3M Innovative Properties Company	Arylalkenyl and arylalkynyl substituted imidazoquinolines
CA2551399A1 (en)	2003-12-30	2005-07-21	3M Innovative Properties Company	Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
WO2005067500A2 (en) *	2003-12-30	2005-07-28	3M Innovative Properties Company	Enhancement of immune responses
WO2005089317A2 (en)	2004-03-15	2005-09-29	3M Innovative Properties Company	Immune response modifier formulations and methods
AU2005228150A1 (en)	2004-03-24	2005-10-13	3M Innovative Properties Company	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
CA2562283A1 (en) *	2004-04-09	2005-11-24	3M Innovative Properties Company	Methods, compositions, and preparations for delivery of immune response modifiers
CA2564855A1 (en) *	2004-04-28	2005-10-28	3M Innovative Properties Company	Compositions and methods for mucosal vaccination
US20050267145A1 (en) *	2004-05-28	2005-12-01	Merrill Bryon A	Treatment for lung cancer
US20080015184A1 (en) *	2004-06-14	2008-01-17	3M Innovative Properties Company	Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
WO2005123080A2 (en)	2004-06-15	2005-12-29	3M Innovative Properties Company	Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
EP1765348B1 (de) *	2004-06-18	2016-08-03	3M Innovative Properties Company	Substituierte imidazochinoline, imidazopyridine sowie imidazonaphthyridine
WO2006009832A1 (en) *	2004-06-18	2006-01-26	3M Innovative Properties Company	Substituted imidazo ring systems and methods
US8026366B2 (en)	2004-06-18	2011-09-27	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006038923A2 (en)	2004-06-18	2006-04-13	3M Innovative Properties Company	Aryl substituted imidazonaphthyridines
WO2006065280A2 (en)	2004-06-18	2006-06-22	3M Innovative Properties Company	Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8541438B2 (en)	2004-06-18	2013-09-24	3M Innovative Properties Company	Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006026470A2 (en) *	2004-08-27	2006-03-09	3M Innovative Properties Company	Hiv immunostimulatory compositions
WO2006028962A2 (en) *	2004-09-02	2006-03-16	3M Innovative Properties Company	1-alkoxy 1h-imidazo ring systems and methods
CA2578975A1 (en)	2004-09-02	2006-03-16	3M Innovative Properties Company	2-amino 1h imidazo ring systems and methods
US20090270443A1 (en) *	2004-09-02	2009-10-29	Doris Stoermer	1-amino imidazo-containing compounds and methods
US20080193468A1 (en) *	2004-09-08	2008-08-14	Children's Medical Center Corporation	Method for Stimulating the Immune Response of Newborns
JP2008515928A (ja) *	2004-10-08	2008-05-15	スリーエムイノベイティブプロパティズカンパニー	Ｄｎａワクチンのためのアジュバント
EP1819364A4 (de) *	2004-12-08	2010-12-29	3M Innovative Properties Co	Immunmodulatorische zusammensetzungen, kombinationen und verfahren
US8080560B2 (en) *	2004-12-17	2011-12-20	3M Innovative Properties Company	Immune response modifier formulations containing oleic acid and methods
AU2005326708C1 (en)	2004-12-30	2012-08-30	3M Innovative Properties Company	Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
JP2008526765A (ja)	2004-12-30	2008-07-24	スリーエムイノベイティブプロパティズカンパニー	皮膚転移の処置
KR20070107685A (ko) *	2004-12-30	2007-11-07	다케다 야쿠힌 고교 가부시키가이샤	１-(２-메틸프로필)-１Ｈ-이미다조[４,５-ｃ][１,５]나프티리딘-４-아민 에탄술포네이트 및１-(２-메틸프로필)-１Ｈ-이미다조[４,５-ｃ][１,５]나프티리딘-４-아민 메탄술포네이트
EP1831226B1 (de)	2004-12-30	2012-08-08	3M Innovative Properties Company	Chirale tetracyklische verbindungen, die interferon biosyntheze induzieren
US8436176B2 (en) *	2004-12-30	2013-05-07	Medicis Pharmaceutical Corporation	Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
AU2006210392A1 (en)	2005-02-04	2006-08-10	Coley Pharmaceutical Group, Inc.	Aqueous gel formulations containing immune response modifiers
JP2008530252A (ja)	2005-02-09	2008-08-07	コーリーファーマシューティカルグループ，インコーポレイテッド	オキシムおよびヒドロキシルアミンで置換されたチアゾロ［４，５−ｃ］環化合物ならびに方法
AU2006212765B2 (en) *	2005-02-09	2012-02-02	3M Innovative Properties Company	Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
CA2597587A1 (en)	2005-02-11	2006-08-17	Coley Pharmaceutical Group, Inc.	Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
JP2008532933A (ja)	2005-02-11	2008-08-21	コーリーファーマシューティカルグループ，インコーポレイテッド	置換イミダゾキノリン類および置換イミダゾナフチリジン類
EP1850849A2 (de)	2005-02-23	2007-11-07	Coley Pharmaceutical Group, Inc.	Verfahren zur vorzugsweisen herbeiführung der biosynthese von interferon
CA2598639A1 (en)	2005-02-23	2006-08-31	Coley Pharmaceutical Group, Inc.	Hydroxyalkyl substituted imidazonaphthyridines
US8158794B2 (en)	2005-02-23	2012-04-17	3M Innovative Properties Company	Hydroxyalkyl substituted imidazoquinoline compounds and methods
EP1851224A2 (de)	2005-02-23	2007-11-07	3M Innovative Properties Company	Hydroxyalkyl-substituierte imidazochinoline
JP2008533148A (ja)	2005-03-14	2008-08-21	スリーエムイノベイティブプロパティズカンパニー	光線性角化症の治療方法
US7943636B2 (en)	2005-04-01	2011-05-17	3M Innovative Properties Company	1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
WO2006107853A2 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	Pyrazolopyridine-1,4-diamines and analogs thereof
CA2605808A1 (en) *	2005-04-25	2006-11-02	3M Innovative Properties Company	Immunostimulatory compositions
ZA200803029B (en) *	2005-09-09	2009-02-25	Coley Pharm Group Inc	Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
AU2006287270A1 (en)	2005-09-09	2007-03-15	Coley Pharmaceutical Group, Inc.	Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
US8889154B2 (en)	2005-09-15	2014-11-18	Medicis Pharmaceutical Corporation	Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
ES2429170T3 (es)	2005-11-04	2013-11-13	3M Innovative Properties Company	1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos
EP1968582A4 (de) *	2005-12-28	2011-02-16	3M Innovative Properties Co	Behandlung von kutanem t-zell-lymphom
EP1988896A4 (de)	2006-02-22	2011-07-27	3M Innovative Properties Co	Konjugate zur modifizierung von immunreaktionen
US8329721B2 (en)	2006-03-15	2012-12-11	3M Innovative Properties Company	Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
US7906506B2 (en)	2006-07-12	2011-03-15	3M Innovative Properties Company	Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
AU2007275815A1 (en) *	2006-07-18	2008-01-24	Wirra Ip Pty. Ltd.	Immune response modifier formulations
CA2659733A1 (en) *	2006-07-31	2008-02-07	3M Innovative Properties Company	Sterilized topical compositions of 1-(2-methylpropyl)-1h-imidazo[4,5-c]quinolin-4-amine
US8178539B2 (en)	2006-09-06	2012-05-15	3M Innovative Properties Company	Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
US20080149123A1 (en)	2006-12-22	2008-06-26	Mckay William D	Particulate material dispensing hairbrush with combination bristles
PT3150586T (pt)	2007-02-23	2020-03-31	Gilead Sciences Inc	Moduladores de propriedades farmacocinéticas de agentes terapêuticos
EA201591353A1 (ru)	2008-05-02	2016-01-29	Джилид Сайэнс, Инк.	Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
US20110033515A1 (en) *	2009-08-04	2011-02-10	Rst Implanted Cell Technology	Tissue contacting material
WO2011084725A1 (en) *	2009-12-21	2011-07-14	3M Innovative Properties Company	4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
DK2606047T3 (en)	2010-08-17	2017-03-27	3M Innovative Properties Co	COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF
EP3153180A1 (de)	2011-06-03	2017-04-12	3M Innovative Properties Company	Heterobifunktionale binder mit polyethylenglykolsegmenten und daraus hergestellte immunantwort-modifizierende konjugate
BR112013031028A2 (pt)	2011-06-03	2016-11-29	3M Innovative Properties Co	conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
US20130023736A1 (en)	2011-07-21	2013-01-24	Stanley Dale Harpstead	Systems for drug delivery and monitoring
AU2013252785B2 (en)	2012-04-27	2017-05-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Use of CpG oligonucleotides co-formulated with an antibiotic to accelarate wound healing
PL2844282T3 (pl)	2012-05-04	2019-11-29	Pfizer	Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
US10835495B2 (en)	2012-11-14	2020-11-17	W. R. Grace & Co.-Conn.	Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
DK4001311T3 (da)	2014-07-09	2026-02-02	Birdie Biopharmaceuticals Inc	Anti-pd-l1/pd-1-kombinationer til behandling af tumorer
US20160058718A1 (en)	2014-09-02	2016-03-03	Michael Basara	Formulation and method of treating chronic wounds and preventing bacterial infections
WO2016063265A2 (pt) *	2014-10-24	2016-04-28	Palmeira De Oliveira Rita Manuela	Formulação tópica para o tratamento de infeções na pele ou mucosas, método de preparação e seus usos
AU2018207283C1 (en)	2017-01-10	2024-05-02	Nektar Therapeutics	Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
CA3086439A1 (en)	2017-12-20	2019-06-27	3M Innovative Properties Company	Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
PL3923923T3 (pl)	2019-02-13	2024-10-07	DEBx Medical Holding B.V.	Kompozycje do usuwania martwiczych lub zakażonych tkanek ze zmian na powierzchni ciała i z jamy ustnej
WO2020226889A1 (en) *	2019-05-07	2020-11-12	Wellstat Therapeutics Corporation	Formulations of uridine triacetate in triacetin
US12605349B2 (en)	2024-09-05	2026-04-21	Orbus Therapeutics, Inc.	Methods of treating grade 3 astrocytoma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA831186B (en) *	1982-03-22	1983-11-30	Upjohn Ltd	Gelled pge2/triacetin solutions
IL73534A (en) *	1983-11-18	1990-12-23	Riker Laboratories Inc	1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1272953A (en) *	1984-10-08	1990-08-21	Yuji Makino	Pharmaceutical composition for external use containing active-type vitamin d.sub.3
EP0258175B1 (de)	1986-07-14	1992-04-01	Sandoz Ag	5-Hetero- oder -Aryl-substituierte Imidazo[2,1-a]isochinoline
US4788064A (en) *	1987-07-31	1988-11-29	Warner-Lambert Company	Transdermal delivery system
US4814173A (en) *	1987-09-08	1989-03-21	Warner-Lambert Company	Silicone elastomer transdermal matrix system
IL92537A (en) *	1988-12-15	1994-04-12	Riker Laboratories Inc	Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
US5238944A (en) *	1988-12-15	1993-08-24	Riker Laboratories, Inc.	Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
EP0385630B1 (de) *	1989-02-27	1996-11-27	Riker Laboratories, Inc.	4-Amino-1H-Imidazo(4,5-c)chinoline als antivirale Mittel
DE69229114T2 (de) *	1991-03-01	1999-11-04	Minnesota Mining And Mfg. Co., Saint Paul	1,2-substituierte 1h-imidazo[4,5-c]chinolin-4-amine
US5389640A (en) *	1991-03-01	1995-02-14	Minnesota Mining And Manufacturing Company	1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE4117249C2 (de) *	1991-05-27	1998-05-14	Christian Dr Stief	Linsidomin zur Behandlung erektiler Dysfunktionen

1996
- 1996-12-03 US US08/759,992 patent/US5939090A/en not_active Expired - Lifetime
1997
- 1997-12-01 AU AU53686/98A patent/AU723897B2/en not_active Ceased
- 1997-12-01 EP EP97950772A patent/EP0942724B1/de not_active Expired - Lifetime
- 1997-12-01 PT PT97950772T patent/PT942724E/pt unknown
- 1997-12-01 IL IL13006597A patent/IL130065A/en not_active IP Right Cessation
- 1997-12-01 KR KR10-1999-7004821A patent/KR100503716B1/ko not_active Expired - Fee Related
- 1997-12-01 AT AT97950772T patent/ATE245422T1/de active
- 1997-12-01 HU HU0000568A patent/HU229599B1/hu not_active IP Right Cessation
- 1997-12-01 ES ES97950772T patent/ES2200206T3/es not_active Expired - Lifetime
- 1997-12-01 WO PCT/US1997/021995 patent/WO1998024436A2/en not_active Ceased
- 1997-12-01 DK DK97950772T patent/DK0942724T3/da active
- 1997-12-01 DE DE69723721T patent/DE69723721T2/de not_active Expired - Lifetime
- 1997-12-01 CA CA002273094A patent/CA2273094C/en not_active Expired - Fee Related
- 1997-12-01 JP JP52574098A patent/JP4615633B2/ja not_active Expired - Fee Related
- 1997-12-01 NZ NZ335821A patent/NZ335821A/en not_active IP Right Cessation
- 1997-12-01 CZ CZ0195599A patent/CZ301713B6/cs not_active IP Right Cessation
- 1997-12-01 BR BRPI9713677-8A patent/BR9713677B1/pt not_active IP Right Cessation
1999
- 1999-06-01 NO NO19992638A patent/NO325684B1/no not_active IP Right Cessation
- 1999-06-04 US US09/325,369 patent/US6365166B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NO992638L (no)	1999-07-16
CZ301713B6 (cs)	2010-06-02
NO325684B1 (no)	2008-07-07
DE69723721T2 (de)	2004-04-15
ATE245422T1 (de)	2003-08-15
US6365166B2 (en)	2002-04-02
CA2273094A1 (en)	1998-06-11
CA2273094C (en)	2005-08-16
ES2200206T3 (es)	2004-03-01
CZ195599A3 (cs)	1999-09-15
IL130065A0 (en)	2000-02-29
JP2001501968A (ja)	2001-02-13
EP0942724B1 (de)	2003-07-23
WO1998024436A3 (en)	1998-08-06
HUP0000568A2 (hu)	2000-10-28
NZ335821A (en)	2001-04-27
JP4615633B2 (ja)	2011-01-19
EP0942724A2 (de)	1999-09-22
AU5368698A (en)	1998-06-29
NO992638D0 (no)	1999-06-01
US20020015715A1 (en)	2002-02-07
PT942724E (pt)	2003-12-31
DK0942724T3 (da)	2003-11-17
HU229599B1 (hu)	2014-02-28
DE69723721D1 (de)	2003-08-28
BR9713677A (pt)	2000-03-28
HUP0000568A3 (en)	2001-01-29
BR9713677B1 (pt)	2009-05-05
US5939090A (en)	1999-08-17
WO1998024436A2 (en)	1998-06-11
KR100503716B1 (ko)	2005-07-26
KR20000069233A (ko)	2000-11-25
AU723897B2 (en)	2000-09-07

Legal Events

Date	Code	Title
2004-11-24	FF	Patent granted
2005-02-20	KB	Patent renewed
2008-01-22	KB	Patent renewed
2011-11-30	KB	Patent renewed
2016-06-30	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US5939090A (en)	1999-08-17	Gel formulations for topical drug delivery
EP0526561B1 (de)	1996-04-03	Mittel zur transdermalen penetration von arzneimitteln
JP2671248B2 (ja)	1997-10-29	薬効または化粧効果成分の浸透性増進方法
EP0871420B1 (de)	2001-09-19	Triacetin zur erhöhung der transdermalen penetration
US20030072814A1 (en)	2003-04-17	Topical pharmaceutical composition for the treatment of warts
CA1315692C (en)	1993-04-06	Pharmaceutical compositions for topical application with systemic action
CA1179600A (en)	1984-12-18	Preparations for dermatoses
EP0662819B1 (de)	1996-04-24	Antiviral wirksame pharmazeutische öl in wasser-emulsion, die 9-[(2-hydroxyethoxy)methyl]-guanin (acyclovir) oder ein salz oder einen ester davon enthält
RU2152784C1 (ru)	2000-07-20	Трансдермальное введение противоэпилептических лекарственных препаратов
JPS63152311A (ja)	1988-06-24	徐放性口腔用製剤
Sciarra et al.	1976	In vitro release of therapeutically active ingredients from polymer matrixes
JPS61268631A (ja)	1986-11-28	経皮吸収性を高めた皮膚外用剤
EP0188538B1 (de)	1989-10-11	Transdermale gabe von azatidin
RU2185807C1 (ru)	2002-07-27	Пролонгированные лекарственные формы местного действия, оказывающие активирующее влияние на иммунную систему
JP2831030B2 (ja)	1998-12-02	３’‐アジド‐３’デオキシチミジンを有効成分とする経皮投与製剤用組成物
JP4885856B2 (ja)	2012-02-29	局所クロモリン製剤
SHIGEYAMA et al.	1999	Mixed base of hydrophilic ointment and purified lanolin to improve the drug release rate and absorption of water of minocycline hydrochloride ointment for treatment of bedsores
KR0178796B1 (ko)	1999-03-20	외용산제
CA2060501A1 (en)	1990-12-14	Anhydrous oil-based liquid suspension for delivering a medicament
JPH0320227A (ja)	1991-01-29	皮膚外用剤
HU200689B (en)	1990-08-28	Process for producing endermic pharmaceutical compositions comprising pyrazolo(1,5-a)pyridine derivatives as active ingredient
JPH11199473A (ja)	1999-07-27	貼付剤用膏体
JPH10139687A (ja)	1998-05-26	皮膚外用液剤
JP2954179B1 (ja)	1999-09-27	パップ剤
JPH0640920A (ja)	1994-02-15	ウイルス感染症処置剤